Global Blood Therapeutics, Inc.
Initiate two global, randomized, placebo-controlled pivotal Phase 3 trials of inclacumab
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Announced plans to initiate two global, randomized, placebo-controlled pivotal Phase 3 trials evaluating the safety and efficacy of inclacumab in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company initiated the two inclacumab Phase 3 trials in July 2021, after the first-half 2021 deadline, as reported in its later 8-K and 10-K filings.
-
A Global Blood Therapeutics, Inc. 10-K filed 2022-02-23
“In July 2021, we initiated two global, randomized, placebo-controlled, pivotal Phase 3 trials evaluating the safety and efficacy of inclacumab, our P-selectin inhibitor” ✓ confirmed on the page
-
A Global Blood Therapeutics, Inc. 8-K filed 2021-08-03
“In July 2021, initiated two global, randomized, placebo-controlled, pivotal Phase 3 trials evaluating the safety and efficacy of inclacumab” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Two pivotal Phase 3 trials of inclacumab
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Global Blood Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C629137-024306 · Corrections policy